Source: Eur Respir J, 49 (6) 1601923; 10.1183/13993003.01923-2016



Rating:

Share or cite this content

Citations should be made in the following way:
Damien Viglino, Ingrid Jullian-Desayes, Mélanie Minoves, Judith Aron-Wisnewsky, Vincent Leroy, Jean-Pierre Zarski, Renaud Tamisier, Marie Joyeux-Faure, Jean-Louis Pépin. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J, 49 (6) 1601923; 10.1183/13993003.01923-2016

Member's Comments

No comment yet.

Related content which might interest you: Non-alcoholic fatty liver disease (NAFLD): A new mechanism for co-morbidities in chronic obstructive pulmonary disease (COPD)? Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Relationship between OSA and non-alcoholic fatty liver disease Source: ERS Conference Year: 2015 Increased risk of obstructive sleep apnoea in patients with non-alcoholic fatty liver disease Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II Year: 2012 Association between obstructive sleep apnea and the severity of non-alcoholic fatty liver disease. Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases Year: 2019 Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? Source: Eur Respir J, 49 (6) 1700546; 10.1183/13993003.00546-2017 Year: 2017 Association between obstructive sleep apnea and nonalcoholic fatty liver disease Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases Year: 2019 The impact of severe obstructive sleep apnea and obesity on nonalcoholic fatty liver disease. Source: International Congress 2017 – Obstructive and central sleep apnoea: consequences and comorbidities Year: 2017 Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease Source: Annual Congress 2011 - Physiology and cardiometabolic comorbidities in obstructive sleep apnoea Year: 2011 In sleep apnea patients nonalcoholic fatty liver disease (NAFLD) is associated with the severity of intermittent hypoxia and more severe endothelial dysfunction Source: Annual Congress 2012 - Sleep disorders in internal medicine Year: 2012 Regulation disorders of pulmonary lipid metabolism in chronic obstructive pulmonary disease Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Impact of non-alcoholic fatty liver disease on late cardiovascular events and death in Chronic Obstructive Pulmonary Disease Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018 Emphysema contribution to the progression of chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 654s Year: 2006 Rhinovirus-infection in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 591s Year: 2002 Periodontitis and chronic obstructive pulmonary disease Source: Annual Congress 2006 - COPD and inflammation Year: 2006 Inflammation and depression in chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 718s Year: 2007 Fat free mass and exacerbation of chronic obstructive pulmonary disease Source: Annual Congress 2007 - COPD and comorbidity Year: 2007 Fatty airways: implications for obstructive disease Source: Eur Respir J, 54 (6) 1900857; 10.1183/13993003.00857-2019 Year: 2019 Anemia in chronic obstructive pulmonary disease Source: Annual Congress 2012 - COPD comorbidities I Year: 2012 Frequency and features of formation of chronic kidney disease (CKD) in patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 Comorbidities in the course of chronic obstructive pulmonary disease Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases Year: 2011